Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

Aug

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

ACS Study Quantifies Financial Burden of Cancer in Older Patients

Transplant Consolidation Improves Survival in Primary CNS Lymphoma

Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL

NCI Names New CCR Director

Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy